120 related articles for article (PubMed ID: 14989185)
1. High rate of virologic failure with once-daily ddI/3TC/TDF.
IAPAC Mon; 2003 Nov; 9(11):279. PubMed ID: 14989185
[No Abstract] [Full Text] [Related]
2. French investigators warn of LPV/TDF/ddI interaction.
Carter M
IAPAC Mon; 2003 Dec; 9(12):315. PubMed ID: 15055164
[No Abstract] [Full Text] [Related]
3. Tenofovir drug interactions: ddI and d4T.
TreatmentUpdate; 2003; 15(2):7. PubMed ID: 12693363
[No Abstract] [Full Text] [Related]
4. Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
Feinberg J
AIDS Clin Care; 2005 Jan; 17(1):7. PubMed ID: 15717373
[No Abstract] [Full Text] [Related]
5. Failure of combination abacavir + tenofovir + lamivudine (3TC).
AIDS Treat News; 2003 Jul; (393):2. PubMed ID: 14679923
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients.
Winters MA; Bosch RJ; Albrecht MA; Katzenstein DA;
J Infect Dis; 2003 Aug; 188(4):537-40. PubMed ID: 12898440
[TBL] [Abstract][Full Text] [Related]
7. The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.
Tung MY; Mandalia S; Bower M; Gazzard B; Nelson M
HIV Med; 2005 May; 6(3):151-4. PubMed ID: 15876280
[TBL] [Abstract][Full Text] [Related]
8. Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.
Bongiovanni M; Gianotti N; Chiesa E; Nasta P; Cicconi P; Capetti A; di Biagio A; Matti A; Tirelli V; Marconi P; de Luca A; Mussini C; Gatti F; Zaccarelli M; Abeli C; Torti C; Antinori A; Castagna A; d'Arminio Monforte A
Infection; 2007 Dec; 35(6):451-6. PubMed ID: 18034204
[TBL] [Abstract][Full Text] [Related]
9. New uses for tenofovir: more questions about d4T.
Proj Inf Perspect; 2003 Jan; (35):15-6. PubMed ID: 12647676
[TBL] [Abstract][Full Text] [Related]
10. Virologic and immunologic efficacy of the tenofovir/didanosine/lamivudine regimen.
Quercia R; Amiel C; Marechal Eda S; Lebrette MG; Thevenet S; Renaud S; Schneider V; Kara A; Guessant S; Pialoux G
J Acquir Immune Defic Syndr; 2006 Jul; 42(3):389-90. PubMed ID: 16763531
[No Abstract] [Full Text] [Related]
11. Editorial comment: a tale of two viruses.
Dieterich DT
AIDS Read; 2002 Oct; 12(10):448-9. PubMed ID: 12408102
[No Abstract] [Full Text] [Related]
12. Anti-HIV agents. Dueling nukes: AZT + 3TC vs. tenofovir + FTC.
TreatmentUpdate; 2005; 17(5):5-7. PubMed ID: 17225279
[No Abstract] [Full Text] [Related]
13. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
[TBL] [Abstract][Full Text] [Related]
14. Meeting notes from ICAAC. Tenofovir + ddI: a combination to avoid.
Sax PE
AIDS Clin Care; 2005 Jan; 17(1):6-7. PubMed ID: 15717372
[No Abstract] [Full Text] [Related]
15. Promising results for tenofovir.
AIDS Patient Care STDS; 2000 Jul; 14(7):396. PubMed ID: 10935058
[No Abstract] [Full Text] [Related]
16. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Exploring once-daily tenofovir + 3TC + abacavir: an argument for clinical-trials-based data.
Becker S; Feinberg J
AIDS Clin Care; 2003 Sep; 15(9):81. PubMed ID: 14669727
[TBL] [Abstract][Full Text] [Related]
17. [First nucleotide analog against HIV. Lowers viral load also in drug resistance].
MMW Fortschr Med; 2002 Aug; 144(33-34):60-1. PubMed ID: 12380157
[No Abstract] [Full Text] [Related]
18. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
[TBL] [Abstract][Full Text] [Related]
19. Tenofovir--long term results from first-line therapy.
TreatmentUpdate; 2003; 15(2):4-6. PubMed ID: 12693361
[No Abstract] [Full Text] [Related]
20. [Tenofovir in Study 903. Also effective and tolerable in first-line therapy].
MMW Fortschr Med; 2002 Aug; 144(33-34):61. PubMed ID: 12380158
[No Abstract] [Full Text] [Related]
[Next] [New Search]
